Skip to main content
| News

Holmusk opens new office in Basel

18.01.2021

Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis. Holmusk has placed a focus on the treatment of mental illnesses.

Nawal Roy, CEO of Holmusk (img: Holmusk)

Holmusk has recently moved into a new location at the Novartis Campus of the Switzerland Innovation Park Basel Area. The life sciences company develops data-driven digital therapies to treat a variety of disorders. Its focus is on mental and neurological illnesses, additionally Holmusk is active in the areas of cardiovascular and renal diseases, as well as diabetes.

The new office in Basel represents Holmusk’s seventh international office and second in Europe. According to Stefan Suter, Head of Holmusk Europe, staffing was a key consideration in the choice of Basel as a location: “In Basel we find multilingual, specialized talent from fresh graduates to seasoned professionals to be part of the data-driven revolution in healthcare”. In addition to current and future employees, the companies already located in Basel were also a significant pull factor for Holmusk. “Basel, with its large ecosystem of global leaders in life sciences offers multiple partnership opportunities and allows direct access to expand business into Germany or France”, explains Nawal Roy, CEO of Holmusk.

Holmusk is planning to build the world’s largest platform for what is known as real-world evidence (RWE), in which data from clinical practice is used to develop treatments. Holmusk has already been active in this area for five years, while the company also managed to successfully raise a total of 21.5 million US dollars in 2020 as part of a Series A financing round.

Switzerland Innovation Park Basel Area is operated by Basel Area Business & Innovation. The investment and innovation promotion agency also supported Holmusk during the process of establishing its business in the region.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.